Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-01-20
2008-09-09
Allen, Marianne P. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023510, C435S069100, C435S320100, C435S325000, C530S397000
Reexamination Certificate
active
07423139
ABSTRACT:
The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin coding region fused to a unique 5′-UTR sequence and a truncated 3′-UTR. The present invention also provides methods of synthesizing large amounts of erythropoietin and in increasing serum erythropoietin level in individuals in need thereof.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4703008 (1987-10-01), Lin
patent: 4801531 (1989-01-01), Frossard
patent: 4879219 (1989-11-01), Wands et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5192659 (1993-03-01), Simons
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5281521 (1994-01-01), Trojanowski et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5688679 (1997-11-01), Powell
patent: WO 86/07594 (1986-12-01), None
Wells, Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Cone et al. “High-Efficiency Gene Transfer Into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus With Broad Mammalian Host Range”, Proc. Natl. Acad. Sci. USA, 81: 6349-6353, 1984.
Jacobs et al. “Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin”, Nature, 313(6005): 806-810, 1985. Abstract.
Kozak “Influences of mRNA Secondary Structure on Initiation by Eukaryotic Ribosomes”, Proc. Natl. Acad. Sci. USA, 83: 2850-2854, 1986.
Kozak “Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs”, Molecular and Cellular Biology, 9(11): 5134-5142, 1989.
Kozak “Effects of Long 5′ Leader Sequences on Initiation by Eukaryotic Ribosomes In Vitro”, Gene Expression, 1(2): 117-125, 1991. Abstract.
Kozak “Structural Features in Eukaryotic mRNAs That Modulate the Initiation of Translation”, The Journal of Biological Chemistry, 266(30): 19867-19870, 1991.
Kozak “At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells”, Journal of Molecular Biology, 196(4): 947-950, 1987. Abstract.
Kozak “An Analysis of 5′-Noncoding Sequences From 699 Vertebrate Messenger RNAs”, Nucleic Acids Research, 15: 8125-8148, 1987.
Kozak “Context Effects and Inefficient Initiation at Non-AUG Codons in Eucaryotic Cell-Free Translation Systems”, Molecular and Cellular Biology, 9(11): 5073-5080, 1989.
Kozak “The Scanning Model for Translation: An Update”, The Journal of Cell Biology, 108: 229-241, 1989.
Lin et al. “Cloning and Expression of the Human Erythropoietin Gene”, Proc. Natl. Acad. Sci. USA, 82: 7580-7584, 1985.
Park et al. “Efficiency of Promoter and Cell Line in High-Level Expression of Erythropoietin”, Biotechnology and Applied Biochemistry, 32: 167-172, 2000.
Pelletier et al. “Insertion Mutagenesis to Increase Secondary Structure Within the 5′ Noncoding Region of A Eukaryotic mRNA Reduces Translational Efficiency”, Cell, 40(3): 515-526, 1985. Abstract.
Allen Marianne P.
DeBerry Regina M
InSight Biopharmaceuticals Ltd.
LandOfFree
High level expression of recombinant human erythropoietin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High level expression of recombinant human erythropoietin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High level expression of recombinant human erythropoietin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3978559